---
annotations:
- type: Pathway Ontology
  value: disease pathway
- type: Pathway Ontology
  value: infectious disease pathway
- type: Disease Ontology
  value: severe acute respiratory syndrome
- type: Disease Ontology
  value: viral infectious disease
authors:
- ReactomeTeam
- DeSl
description: This pathway, SARS-CoV-2 infection of human cells (COVID-19), was initially
  generated via electronic inference from the manually curated and reviewed Reactome
  SARS-CoV-1 (Human SARS coronavirus) infection pathway. The inference process created
  SARS-CoV-2 events corresponding to each event in the SARS-CoV-1 pathway and populated
  those events with SARS-CoV-2 protein-containing physical entities based on orthology
  to SARS-CoV-1 proteins (https://reactome.org/documentation/inferred-events). All
  of these computationally created events and entities have been reviewed by Reactome
  curators and modified as appropriate where recently published experimental data
  indicate the existences of differences between the molecular details of the SARS-CoV-1
  and SARS-CoV-2 infection pathways.<br><br>SARSâ€‘CoVâ€‘2 infection begins with the
  binding of viral S (spike) protein to cell surface angiotensin converting enzyme
  2 (ACE2) and endocytosis of the bound virion. Within the endocytic vesicle, host
  proteases mediate cleavage of S protein into S1 and S2 fragments, leading to S2â€‘mediated
  fusion of the viral and host endosome membranes and release of the viral capsid
  into the host cell cytosol. The capsid is uncoated to free the viral genomic RNA,
  whose capâ€‘dependent translation produces polyprotein pp1a and, by means of a 1â€‘base
  frameshift, polyprotein pp1ab. Autoproteolytic cleavage of pp1a and pp1ab generates
  15 or 16 nonstructural proteins (nsps) with various functions. Importantly, the
  RNA dependent RNA polymerase (RdRP) activity is encoded in nsp12. Nsp3, 4, and 6
  induce rearrangement of the cellular endoplasmic reticulum membrane to form cytosolic
  double membrane vesicles (DMVs) where the viral replication transcription complex
  is assembled and anchored. With viral genomic RNA as a template, viral replicaseâ€‘transcriptase
  synthesizes a full length negative sense antigenome, which in turn serves as a template
  for the synthesis of new genomic RNA. The replicaseâ€‘transcriptase can also switch
  template during discontinuous transcription of the genome at transcription regulated
  sequences to produce a nested set of negativeâ€‘sense subgenomic (sg) RNAs, which
  are used as templates for the synthesis of positiveâ€‘sense sgRNAs that are translated
  to generate viral proteins. Finally, viral particle assembly occurs in the ER Golgi
  intermediate compartment (ERGIC). Viral M protein provides the scaffold for virion
  morphogenesis (Hartenian et al. 2020; Fung & Liu 2019; Masters 2006).  View original
  pathway at [http://www.reactome.org/PathwayBrowser/#DIAGRAM=9694516 Reactome].
last-edited: 2021-01-25
organisms:
- Homo sapiens
redirect_from:
- /index.php/Pathway:WP5021
- /instance/WP5021
schema-jsonld:
- '@context': https://schema.org/
  '@id': https://wikipathways.github.io/pathways/WP5021.html
  '@type': Dataset
  creator:
    '@type': Organization
    name: WikiPathways
  description: This pathway, SARS-CoV-2 infection of human cells (COVID-19), was initially
    generated via electronic inference from the manually curated and reviewed Reactome
    SARS-CoV-1 (Human SARS coronavirus) infection pathway. The inference process created
    SARS-CoV-2 events corresponding to each event in the SARS-CoV-1 pathway and populated
    those events with SARS-CoV-2 protein-containing physical entities based on orthology
    to SARS-CoV-1 proteins (https://reactome.org/documentation/inferred-events). All
    of these computationally created events and entities have been reviewed by Reactome
    curators and modified as appropriate where recently published experimental data
    indicate the existences of differences between the molecular details of the SARS-CoV-1
    and SARS-CoV-2 infection pathways.<br><br>SARSâ€‘CoVâ€‘2 infection begins with
    the binding of viral S (spike) protein to cell surface angiotensin converting
    enzyme 2 (ACE2) and endocytosis of the bound virion. Within the endocytic vesicle,
    host proteases mediate cleavage of S protein into S1 and S2 fragments, leading
    to S2â€‘mediated fusion of the viral and host endosome membranes and release of
    the viral capsid into the host cell cytosol. The capsid is uncoated to free the
    viral genomic RNA, whose capâ€‘dependent translation produces polyprotein pp1a
    and, by means of a 1â€‘base frameshift, polyprotein pp1ab. Autoproteolytic cleavage
    of pp1a and pp1ab generates 15 or 16 nonstructural proteins (nsps) with various
    functions. Importantly, the RNA dependent RNA polymerase (RdRP) activity is encoded
    in nsp12. Nsp3, 4, and 6 induce rearrangement of the cellular endoplasmic reticulum
    membrane to form cytosolic double membrane vesicles (DMVs) where the viral replication
    transcription complex is assembled and anchored. With viral genomic RNA as a template,
    viral replicaseâ€‘transcriptase synthesizes a full length negative sense antigenome,
    which in turn serves as a template for the synthesis of new genomic RNA. The replicaseâ€‘transcriptase
    can also switch template during discontinuous transcription of the genome at transcription
    regulated sequences to produce a nested set of negativeâ€‘sense subgenomic (sg)
    RNAs, which are used as templates for the synthesis of positiveâ€‘sense sgRNAs
    that are translated to generate viral proteins. Finally, viral particle assembly
    occurs in the ER Golgi intermediate compartment (ERGIC). Viral M protein provides
    the scaffold for virion morphogenesis (Hartenian et al. 2020; Fung & Liu 2019;
    Masters 2006).  View original pathway at [http://www.reactome.org/PathwayBrowser/#DIAGRAM=9694516
    Reactome].
  keywords:
  - 'VHL '
  - 'pp1a-nsp3 '
  - nsp1
  - tetramer:glycosylated-ACE2
  - 'CTSL(114-288) '
  - Ub
  - N-glycan-PALM-Spike
  - 'pp1ab-nsp1 '
  - 'MGAT4C '
  - pp1ab-nsp3-4
  - 'PARP14 '
  - nsp9 dimer
  - 'CHMP4C '
  - 'GSK3B '
  - 'SARS-CoV-2 nascent genomic RNA complement (minus strand) with mismatched 3''
    nucleotide '
  - 'phospho-SUMO1-K62-ADPr-p-S177-Ncap '
  - nsp7:nsp8:nsp12:nsp14:nsp10:nsp13:nsp15
  - 'ST3GAL2 '
  - S-adenosyl-L-methionine
  - 'pp1a-nsp8 '
  - pp1ab-nsp7
  - 3CLp
  - 'm7G(5'')pppAm-capped,polyadenylated mRNA7 '
  - di-antennary
  - 'SUMO1-C93-UBE2I '
  - 9b
  - 'NHC '
  - 'TMPRSS2 '
  - 'm7GpppA-mRNA7 '
  - TMPRSS2:TMPRSS2
  - 'UBB(77-152) '
  - unfolded Spike
  - S-adenosyl-L-homocysteine
  - 'S1:S2:M:E:encapsidated SARS-CoV-2 genomic RNA: 7a:O-glycosyl 3a tetramer'
  - 'STT3A '
  - nucleotide
  - 'm7GpppA-mRNA5 '
  - 'mRNA4 minus strand '
  - nsp4
  - nucleoside
  - 'CHMP6 '
  - phospho-p-S177,S181,S185,S187,S189,S191,S195,T199,S203,S207-N
  - 'pp1ab-nsp12 '
  - RNA
  - RB1
  - nsp7:nsp8:nsp12:nsp14:nsp10
  - phospho-p-S177-Ncap
  - 'm7G(5'')pppAm-capped SARS-CoV-2 genomic RNA complement (minus strand) '
  - 'GSK3A '
  - RNA:O-glycosyl 3a
  - m7G(5')pppAm-capped
  - pp1ab-nsp9
  - 'm7G(5'')pppAm-mRNA9 '
  - (plus strand)
  - 'UBC(305-380) '
  - 'm7G(5'')pppAm-mRNA4 '
  - 'm7G(5'')pppAm-capped,polyadenylated-mRNA9 '
  - 'tri-antennary N-glycan-PALM-Spike '
  - m7GpppA-SARS-CoV-2
  - pp1ab
  - 'N-glycan pp1ab-nsp3 '
  - pp1a-nsp10
  - 3xPalmC-E
  - 'mRNA6 minus strand '
  - 'CHMP7 '
  - 'PARP16 '
  - 'UBC(229-304) '
  - dimer:Î±-Ketoamides
  - nsp3:nsp4:nsp6
  - VHL
  - 'UBB(1-76) '
  - (Man)9 (PP-Dol)1
  - primer:RTC
  - 'PARP6 '
  - SARS-CoV-2
  - gRNA with secondary
  - Spike trimer
  - 'CHMP3 '
  - 'm7GpppA-mRNA3 '
  - strand):RTC
  - pp1ab-nsp15
  - 3a tetramer
  - SARS-CoV-2 gRNA:RTC
  - 'M '
  - SUMO1:C93-UBE2I
  - 'pp1ab-nsp13 '
  - 'N-glycan pp1ab-nsp3-4 '
  - SARS coronavirus
  - phospho-ADPr-p-S177-Ncap
  - 'mRNA7a minus strand '
  - 'UBC(153-228) '
  - m7G(5')pppAm-capped,polyadenylated mRNA2
  - 'GANAB '
  - Host Derived Lipid
  - TMPRSS2 inhibitors
  - 'glycosylated-ACE2 '
  - RNA (plus strand)
  - pp1a-3CL
  - 'm7G(5'')pppAm-capped,polyadenylated mRNA3 '
  - VCP
  - 'pp1ab-nsp14 '
  - M lattice
  - 'PIK3C3 '
  - 'RPN2 '
  - Ub-3xPalmC-E
  - 3CLp dimer
  - pp1a-nsp8
  - gRNA:RTC:RNA primer
  - 'PIK3R4 '
  - pp1a
  - 'TUSC3(1-348) '
  - 7a:O-glycosyl
  - glycosylated-ACE2
  - NTP
  - nsp13:DDX5
  - pp1a-nsp11
  - beta-D-glucose
  - 'mRNA7b minus strand '
  - 'ST3GAL3 '
  - Î±-Ketoamides
  - 'm7G(5'')pppAm-mRNA2 '
  - 'ST6GALNAC2 '
  - 'mRNA6 '
  - CTSL:CTSL inhibitors
  - 'm7G(5'')pppAm-capped,polyadenylated mRNA2 '
  - 'mRNA5 minus strand '
  - SUMO-p-Ncap
  - (minus strand)
  - N
  - fully glycosylated
  - 'N-glycan pp1a-nsp3 '
  - phospho-SUMO1-K62-ADPr-p-S177-Ncap
  - 'S3:M:E:encapsidated '
  - pentamer
  - nascent M
  - GSK3
  - GSK3B
  - 'pp1ab-nsp15 '
  - '7a '
  - 'UBC(533-608) '
  - MGAT5
  - 'high-mannose N-glycan-PALM-Spike '
  - CTSL inhibitors
  - 'm7G(5'')pppAm-capped,polyadenylated mRNA6 '
  - 'ZCRB1 '
  - ESCRT-III
  - 'ST6GALNAC3 '
  - MAN2A1
  - N-glycan nsp3-4
  - pp1a-nsp7
  - 14-sugar N-glycan
  - pp1ab-nsp6
  - 'mRNA9 '
  - nsp16:VHL
  - nsp7:nsp8:nsp12:nsp14:nsp10:nsp13
  - 'm7GpppA-mRNA8 '
  - 'S1:S2:M:E:'
  - 'pp1a-nsp9 '
  - 'UBC(609-684) '
  - pp1ab-nsp5
  - structure
  - nsp7:nsp8:nsp12
  - nsp3
  - nsp15 hexamer
  - N-glycan M
  - GALNT1
  - 'pp1a-nsp1 '
  - 'DDOST '
  - OST complex
  - 'm7GpppA-mRNA6 '
  - 'UBC(457-532) '
  - 'pp1a-nsp2 '
  - 'pp1ab-nsp7 '
  - ATP
  - m7G(5')pppAm-capped,polyadenylated-mRNA9
  - m7G(5')pppAm-capped,polyadenylated mRNA5
  - pp1ab-nsp12
  - nsp15:RB1
  - N-glycan folded
  - 'pp1ab-nsp2 '
  - nsp10
  - 'RPS27A(1-76) '
  - 'pp1a-nsp6 '
  - protein:encapsidated SARS-CoV-2 genomic RNA
  - strand subgenomic
  - high-mannose
  - 'PARP10 '
  - 'complex N-glycan-PALM-Spike S1 Fragment '
  - 'pp1a-nsp1-4 '
  - 'N-glycan M '
  - m7G(5')pppAm-capped,polyadenylated mRNA3
  - genomic RNA
  - sialyltransferases
  - 'm7G(5'')pppAm-capped,polyadenylated mRNA4 '
  - CMP
  - nsp8
  - pp1ab-nsp13
  - tetramer
  - gRNA:RTC:nascent
  - N-glycan nsp4
  - ADP
  - 'BECN1 '
  - 'mRNA7a '
  - a nucleotide sugar
  - NAM
  - 'HCQ '
  - 'RNA:'
  - 'pp1ab-nsp4 '
  - inhibitors
  - Pi
  - 'RPN1 '
  - 'UVRAG '
  - ZCRB1:m7G(5')pppAm-capped, polyadenylated SARS-CoV-2 genomic RNA (plus strand)
  - mRNAs
  - lattice:E
  - 'MOGS '
  - CQ2+, HCQ2+
  - 'ST6GAL1 '
  - Spike
  - N-glycan nsp3
  - MGAT4s
  - 'complex N-glycan-PALM-Spike S2 Fragment '
  - 5'-diphosphate(3-)
  - pp1a-nsp1-4
  - 'CHMP4B '
  - nucleotide-sugar
  - Bilayer Membrane
  - 'pp1a-3CL '
  - 'mRNA9 minus strand '
  - 7a
  - trimer
  - 3a:membranous
  - FURIN
  - 'UBE2I-G97-SUMO1 '
  - 'mRNA5 '
  - nsp5
  - ER
  - 'ST6GALNAC4 '
  - O-glycosyl 3a
  - Cathepsin L1
  - NAD+
  - 'CHMP4A '
  - 'teicoplanin '
  - M
  - genomic
  - UVRAG complex
  - 'MAN1B1 '
  - 'pp1ab-nsp1-4 '
  - palmitoyl-CoA
  - GalNAc-O-3a
  - 'camostat '
  - 'SARS-CoV-2 nascent genomic RNA complement (minus strand) '
  - polyadenylated
  - 'mRNA8 '
  - ER-alpha-glucosidase
  - RTC
  - 'm7G(5'')pppAm-capped,polyadenylated mRNA8 '
  - 'm7G(5'')pppAm-capped,polyadenylated mRNA5 '
  - RTC inhibitors
  - 'CQ2+ '
  - DDX5
  - SARS-CoV-2 genomic
  - 'O-glycosyl 3a '
  - Man(9) N-glycan
  - 'PARP4 '
  - 'Li<sup>+</sup> '
  - 'MGAT4B '
  - 'DDX5 '
  - 3a
  - MGAT1
  - 'UBC(77-152) '
  - 'CHMP2B '
  - nsp7:nsp8
  - 'mRNA8 minus strand '
  - nsp16:nsp10
  - pp1ab-nsp10
  - 'pp1ab-nsp3-4 '
  - 'pp1ab-nsp3 '
  - 'N-glycan pp1ab-nsp4 '
  - 'pp1a '
  - SARS-CoV-2 minus
  - 'PARP9 '
  - ACE2
  - 'mRNA4 '
  - PPi
  - nascent E
  - UDP
  - 'm7G(5'')pppAm-mRNA5 '
  - Ncap
  - 'm7G(5'')pppAm-mRNA8 '
  - structure:RTC
  - CQ, HCQ
  - 'pp1ab-nsp16 '
  - RNA minus
  - 'pp1ab-nsp10 '
  - 'pp1ab-nsp9 '
  - ER-alpha
  - 'N-glycan pp1a-nsp3-4 '
  - Ncap tetramer
  - 'pp1a-nsp3-4 '
  - strand):RTC:RTC
  - 'mRNA3 '
  - 'fully glycosylated Spike '
  - pp1a-nsp6
  - 'mRNA2 '
  - tri-antennary
  - 'mRNA7b '
  - nsp8:MAP1LC3B
  - pp1a-nsp6-11
  - pp1ab-nsp14
  - SARS-CoV-2 gRNA
  - 'MAP1LC3B '
  - complement (minus
  - GSKi
  - 'm7GpppA-mRNA9 '
  - 'UBC(1-76) '
  - CANX
  - m7G(5')pppAm-SARS-CoV-2 plus strand subgenomic mRNAs
  - 'UBC(381-456) '
  - 'mRNA3 minus strand '
  - 'CTSL(292-333) '
  - S1:S2:M lattice:E
  - subgenomic mRNAs
  - 'di-antennary N-glycan-PALM-Spike '
  - PARPs
  - m7G(5')pppAm-capped,
  - 'RNA: 7a:O-glycosyl'
  - nsp7
  - 'ST3GAL1 '
  - nsp10:nsp14
  - strand:RTC
  - nsp9
  - 'm7GpppA-mRNA4 '
  - 'pp1ab-nsp8 '
  - FUT8
  - 7a:O-glycosyl 3a
  - 'm7G(5'')pppAm-mRNA6 '
  - RNA minus strand
  - 'UBA52(1-76) '
  - pp1ab-nsp8
  - 'mRNA2 minus strand '
  - 'compound 11r '
  - UBE2I
  - MGAT2
  - nsp1-4
  - 'm7G(5'')pppAm-capped, polyadenylated SARS-CoV-2 genomic RNA (plus strand) '
  - CoA-SH
  - DOLP
  - protein
  - 'ST3GAL4 '
  - (Glc)3 (GlcNAc)2
  - 'Host Derived Lipid Bilayer Membrane '
  - nsp2
  - 'CHMP2A '
  - nsp3-4
  - GSK3B:GSKi
  - pp1ab-nsp1-4
  - 'm7G(5'')pppAm-mRNA3 '
  - SARS-CoV-2 plus
  - 'm7GpppA-mRNA2 '
  - '1-deoxynojirimycin '
  - nascent Spike
  - RNA:7a:O-glycosyl
  - CMP-Neu5Ac
  - 'RNA primer '
  - 'pp1a-nsp4 '
  - MAN1B1,EDEM2
  - 'RB1 '
  - S3:M:E:encapsidated
  - m7G(5')pppAm-capped,polyadenylated mRNA4
  - 'm7G(5'')pppAm-mRNA7 '
  - N-glycan unfolded
  - 'pp1ab-nsp5 '
  - nsp6
  - 'pp1ab-nsp6 '
  - ZCRB1
  - nsp3:nsp4
  - pp1a dimer
  - pp1a-nsp9
  - GTP
  - RNA complement
  - 'pp1a-nsp10 '
  - encapsidated
  - MAP1LC3B
  - 'MGAT4A(1-535) '
  - H+
  - N-glycan
  - plus strand
  - 'DAD1 '
  - gRNA:RTC:RNA
  - with mismatched
  - 'Ub-3xPalmC-E '
  - 'EDEM2 '
  - 'pp1a-nsp7 '
  - MOGS
  - H2O
  - TMPRSS2
  - 'PRKCSH '
  - 'N-glycan pp1a-nsp4 '
  - UDP-GalNAc
  - m7GpppA-capped
  - 'PARP8 '
  - dimer:SARS-CoV-2
  - alpha-glucosidases
  - NMP
  - 5'-diphosphate(3âˆ’)
  - 'MAGT1 '
  - glucosidases:ER-alpha glucosidase inhibitors
  - pp1ab-nsp16
  - N-glycan E
  - 'UBB(153-228) '
  license: CC0
  name: SARS-CoV-2 Infection
seo: CreativeWork
title: SARS-CoV-2 Infection
wpid: WP5021
---